Amgen's Q2 2023 earnings call highlighted strong performance, driven by robust volume growth across therapeutic areas and geographic regions, particularly in Asia Pacific. Record sales for several key brands, including Prolia and Repatha, supported the positive outlook.  Management expressed confidence in the pipeline and the upcoming Horizon acquisition, while also acknowledging challenges with Otezla due to competitive pressures.  The positive data from tarlatamab and LUMAKRAS clinical trials are expected to significantly impact the market share.
[2]
